182 related articles for article (PubMed ID: 18851917)
1. Modular synthesis of non-peptidic bivalent NPY Y1 receptor antagonists.
Weiss S; Keller M; Bernhardt G; Buschauer A; König B
Bioorg Med Chem; 2008 Nov; 16(22):9858-66. PubMed ID: 18851917
[TBL] [Abstract][Full Text] [Related]
2. Bivalent argininamide-type neuropeptide y y(1) antagonists do not support the hypothesis of receptor dimerisation.
Keller M; Teng S; Bernhardt G; Buschauer A
ChemMedChem; 2009 Oct; 4(10):1733-45. PubMed ID: 19672917
[TBL] [Abstract][Full Text] [Related]
3. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN
J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
Sautel M; Rudolf K; Wittneben H; Herzog H; Martinez R; Munoz M; Eberlein W; Engel W; Walker P; Beck-Sickinger AG
Mol Pharmacol; 1996 Aug; 50(2):285-92. PubMed ID: 8700135
[TBL] [Abstract][Full Text] [Related]
5. Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis of a tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist.
Keller M; Pop N; Hutzler C; Beck-Sickinger AG; Bernhardt G; Buschauer A
J Med Chem; 2008 Dec; 51(24):8168-72. PubMed ID: 19053784
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and characterization of the first fluorescent nonpeptide NPY Y1 receptor antagonist.
Schneider E; Keller M; Brennauer A; Hoefelschweiger BK; Gross D; Wolfbeis OS; Bernhardt G; Buschauer A
Chembiochem; 2007 Nov; 8(16):1981-8. PubMed ID: 17876753
[TBL] [Abstract][Full Text] [Related]
7. Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools.
Keller M; Erdmann D; Pop N; Pluym N; Teng S; Bernhardt G; Buschauer A
Bioorg Med Chem; 2011 May; 19(9):2859-78. PubMed ID: 21493077
[TBL] [Abstract][Full Text] [Related]
8. Antagonistic properties of centrally truncated analogs of [D-Trp(32)]NPY.
Balasubramaniam A; Ujhelyi M; Borchers M; Huang Y; Zhai W; Zhou Y; Johnson M; Sheriff S; Fischer JE
J Med Chem; 1996 Mar; 39(5):1142-7. PubMed ID: 8676351
[TBL] [Abstract][Full Text] [Related]
9. Application of the guanidine-acylguanidine bioisosteric approach to argininamide-type NPY Y₂ receptor antagonists.
Pluym N; Brennauer A; Keller M; Ziemek R; Pop N; Bernhardt G; Buschauer A
ChemMedChem; 2011 Sep; 6(9):1727-38. PubMed ID: 21692185
[TBL] [Abstract][Full Text] [Related]
10. NPY Y1 antagonists: structure-activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structures.
Aiglstorfer I; Uffrecht A; Gessele K; Moser C; Schuster A; Merz S; Malawska B; Bernhardt G; Dove S; Buschauer A
Regul Pept; 1998 Sep; 75-76():9-21. PubMed ID: 9802389
[TBL] [Abstract][Full Text] [Related]
11. [3H]-BIBP3226 and [3H]-NPY binding to intact SK-N-MC cells and CHO cells expressing the human Y1 receptor.
Vanderheyden PM; Van Liefde I; de Backer JP; Vauquelin G
J Recept Signal Transduct Res; 1998; 18(4-6):363-85. PubMed ID: 9879066
[TBL] [Abstract][Full Text] [Related]
12. Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors.
Keller M; Kaske M; Holzammer T; Bernhardt G; Buschauer A
Bioorg Med Chem; 2013 Nov; 21(21):6303-22. PubMed ID: 24074877
[TBL] [Abstract][Full Text] [Related]
13. Involvement of neuropeptide Y Y1 receptors in the regulation of LH and GH cells in the pituitary of the catfish, Clarias batrachus: an immunocytochemical study.
Mazumdar M; Lal B; Sakharkar AJ; Deshmukh M; Singru PS; Subhedar N
Gen Comp Endocrinol; 2006 Nov; 149(2):190-6. PubMed ID: 16828090
[TBL] [Abstract][Full Text] [Related]
14. 1,3-Disubstituted benzazepines as novel, potent, selective neuropeptide Y Y1 receptor antagonists.
Murakami Y; Hara H; Okada T; Hashizume H; Kii M; Ishihara Y; Ishikawa M; Shimamura M; Mihara S; Kato G; Hanasaki K; Hagishita S; Fujimoto M
J Med Chem; 1999 Jul; 42(14):2621-32. PubMed ID: 10411482
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226.
Aiglstorfer I; Hendrich I; Moser C; Bernhardt G; Dove S; Buschauer A
Bioorg Med Chem Lett; 2000 Jul; 10(14):1597-600. PubMed ID: 10915060
[TBL] [Abstract][Full Text] [Related]
16. [(3)H]UR-PLN196: a selective nonpeptide radioligand and insurmountable antagonist for the neuropeptide Y Y(2) receptor.
Pluym N; Baumeister P; Keller M; Bernhardt G; Buschauer A
ChemMedChem; 2013 Apr; 8(4):587-93. PubMed ID: 23361914
[TBL] [Abstract][Full Text] [Related]
17. N(G)-Acyl-argininamides as NPY Y(1) receptor antagonists: Influence of structurally diverse acyl substituents on stability and affinity.
Weiss S; Keller M; Bernhardt G; Buschauer A; König B
Bioorg Med Chem; 2010 Sep; 18(17):6292-304. PubMed ID: 20688523
[TBL] [Abstract][Full Text] [Related]
18. Modeling of neuropeptide receptors Y1, Y4, Y5, and docking studies with neuropeptide antagonist.
Jois SD; Nagarajarao LM; Prabhakaran M; Balasubramaniam A
J Biomol Struct Dyn; 2006 Apr; 23(5):497-508. PubMed ID: 16494499
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of new hydrazide derivatives as neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
Juanenea L; Galiano S; Erviti O; Moreno A; Pérez S; Aldana I; Monge A
Bioorg Med Chem; 2004 Sep; 12(17):4717-23. PubMed ID: 15358298
[TBL] [Abstract][Full Text] [Related]
20. GPC receptors and not ligands decide the binding mode in neuropeptide Y multireceptor/multiligand system.
Lindner D; van Dieck J; Merten N; Mörl K; Günther R; Hofmann HJ; Beck-Sickinger AG
Biochemistry; 2008 Jun; 47(22):5905-14. PubMed ID: 18457425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
